drugset / Trial / NCT00881452

A Trial of CM-AT in Children With Autism

NCT00881452 ↗

Phase 3 Completed 182 enrolled Curemark
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether CM-AT is safe and effective in treating the core symptoms of autism.

Timeline

Start
2009-05
Primary completion
2011-06
Completion
2011-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Luminenz-AT Protein / enzyme biologic 900 mg —

Indications